In a third study reported on at last week’s American College of Rheumatology’s (ACR) annual meeting in San Francisco, a team led Dr. Kimberly Liang, assistant professor at the University of Pittsburgh, found additional evidence that there is a link between RA and diastolic dysfunction. [...]
|
|||||||
 |
The FDA ordered that the class of drugs known as TNF blockers carry a warning on the packaging that their use carries the risk of developing a potentially deadly fungal disease called histoplasmosis. [...] Rheumatoid arthritis (RA) patients have been treated with several different drugs, including Enbrel (etanercept) and methotrexate. Now a study conducted in the United Kingdom indicates that treatment with a combination of Enbrel (an anti-TNF), and methotrexate increases the remission rate. Nearly 550 RA patients from Europe, Asia, Australia and Latin America, none of whom had used methotrexate, [...] Etanercept, marketed under the name Enbrel, is a drug that belongs to the class of drugs known as tumor necrosis factor (TNF)-alpha blocker. It is used primarily to treat rheumatoid arthritis, but has also been approved for use in treating polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis. On May 1st, the U.S. Food [...] Fascinating news today about an 81 year-old retired physician with Alzheimer’s disease who received an injection of etanercept, under the brand name of Enbrel, a medication that is used to treat rheumatoid arthritis (RA). Prior to the injection the patient was in relatively good health but he was agitated and could not remember what state he was [...] |
  
|
|||||
|
Copyright © 2010 Current Arthritis News and Research - All Rights Reserved
|
|||||||
Recent Comments